121 related articles for article (PubMed ID: 32843426)
1. Dual inhibition of BRAF and mTOR in
Sen S; Tanaka R; Khatua S; Zaky W; Janku F; Penas-Prado M; Weathers SP; Behrang A; Roszik J; Subbiah V
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843426
[TBL] [Abstract][Full Text] [Related]
2. Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors.
Mulcahy Levy JM; Foreman NK; Thorburn A
Autophagy; 2014; 10(11):2077-8. PubMed ID: 25484091
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors.
Prabowo AS; Iyer AM; Veersema TJ; Anink JJ; Schouten-van Meeteren AY; Spliet WG; van Rijen PC; Ferrier CH; Capper D; Thom M; Aronica E
Brain Pathol; 2014 Jan; 24(1):52-66. PubMed ID: 23941441
[TBL] [Abstract][Full Text] [Related]
4. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
5.
Kakkar A; Majumdar A; Pathak P; Kumar A; Kumari K; Tripathi M; Sharma MC; Suri V; Tandon V; Chandra SP; Sarkar C
Neurol India; 2017; 65(5):1076-1082. PubMed ID: 28879901
[TBL] [Abstract][Full Text] [Related]
6. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
7. BRAF Inhibition in
Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
[TBL] [Abstract][Full Text] [Related]
8. Alterations in BRAF gene, and enhanced mTOR and MAPK signaling in dysembryoplastic neuroepithelial tumors (DNTs).
Kakkar A; Majumdar A; Kumar A; Tripathi M; Pathak P; Sharma MC; Suri V; Tandon V; Chandra SP; Sarkar C
Epilepsy Res; 2016 Nov; 127():141-151. PubMed ID: 27599148
[TBL] [Abstract][Full Text] [Related]
9. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
10. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.
Faustino A; Couto JP; Pópulo H; Rocha AS; Pardal F; Cameselle-Teijeiro JM; Lopes JM; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1139-49. PubMed ID: 22549934
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.
Wang H; Long-Boyle J; Winger BA; Nicolaides T; Mueller S; Prados M; Ivaturi V
J Clin Pharmacol; 2020 Sep; 60(9):1209-1219. PubMed ID: 32476174
[TBL] [Abstract][Full Text] [Related]
12. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
[TBL] [Abstract][Full Text] [Related]
13. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
[TBL] [Abstract][Full Text] [Related]
14. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
16. Targeting BRAF in pediatric brain tumors.
Kieran MW
Am Soc Clin Oncol Educ Book; 2014; ():e436-40. PubMed ID: 24857135
[TBL] [Abstract][Full Text] [Related]
17. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
[TBL] [Abstract][Full Text] [Related]
18.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
19. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
20. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
